Kura Oncology, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging -1.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.89 | $-0.77 | +13.5% | Beat | |
| Q1 FY26 | $-0.88 | $-0.83 | +5.7% | Beat | |
| Q4 FY25 | $-0.72 | $-0.92 | -27.8% | Miss | |
| Q3 FY25 | $-0.57 | $-0.85 | -49.1% | Miss | |
| Q2 FY25 | not reported | $-0.75 | not reported | not reported | |
| Q1 FY25 | $-0.51 | $-0.66 | -29.4% | Miss | |
| Q4 FY24 | not reported | $-0.22 | not reported | not reported | |
| Q3 FY24 | $-0.64 | $-0.63 | +1.6% | Beat | |
| Q2 FY24 | $-0.63 | $-0.59 | +6.3% | Beat | |
| Q1 FY24 | $-0.56 | $-0.59 | -5.4% | Miss | |
| Q4 FY23 | $-0.56 | $-0.55 | +1.8% | Beat | |
| Q3 FY23 | $-0.56 | $-0.50 | +10.7% | Beat |
Back to KURA overview · KURA holders · KURA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.